Interpace Diagnostics Group (IDXG) Receives New Coverage from Analysts at Dawson James
Dawson James assumed coverage on shares of Interpace Diagnostics Group (NASDAQ:IDXG) in a report published on Wednesday morning. The firm issued a buy rating and a $4.00 target price on the business services provider’s stock.
IDXG has been the topic of several other research reports. HC Wainwright set a $3.00 price target on Interpace Diagnostics Group and gave the company a buy rating in a research note on Friday, August 10th. Maxim Group set a $3.00 price target on Interpace Diagnostics Group and gave the company a buy rating in a research note on Thursday, July 19th. ValuEngine upgraded Interpace Diagnostics Group from a sell rating to a hold rating in a research note on Friday, August 10th. LADENBURG THALM/SH SH began coverage on Interpace Diagnostics Group in a research report on Friday, June 22nd. They set a buy rating and a $2.25 price objective on the stock. Finally, Zacks Investment Research raised Interpace Diagnostics Group from a sell rating to a hold rating in a research report on Wednesday, July 18th. One equities research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Interpace Diagnostics Group currently has an average rating of Buy and an average price target of $3.17.
Shares of Interpace Diagnostics Group stock opened at $1.36 on Wednesday. The firm has a market cap of $39.46 million, a PE ratio of -1.68 and a beta of 2.36. Interpace Diagnostics Group has a 12 month low of $0.77 and a 12 month high of $1.78.
An institutional investor recently bought a new position in Interpace Diagnostics Group stock. Essex Investment Management Co. LLC acquired a new stake in shares of Interpace Diagnostics Group Inc (NASDAQ:IDXG) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 302,172 shares of the business services provider’s stock, valued at approximately $465,000. Essex Investment Management Co. LLC owned approximately 1.06% of Interpace Diagnostics Group at the end of the most recent reporting period. 12.31% of the stock is currently owned by institutional investors and hedge funds.
Interpace Diagnostics Group Company Profile
Interpace Diagnostics Group, Inc develops and commercializes molecular diagnostic tests to detect genetic and other molecular alterations associated with gastrointestinal and endocrine cancers. It offers PancraGEN, a pancreatic cyst and pancreaticobiliary solid lesion molecular test that helps physicians better assess risk of pancreaticobiliary cancers using its proprietary PathFinder platform; ThyGenX, an oncogenic mutation panel that helps identify malignant thyroid nodules; and ThyraMIR, an microRNA gene expression assay that helps to classify risk of cancer in thyroid nodules.
Recommended Story: What is the 52-week high/low?
Receive News & Ratings for Interpace Diagnostics Group Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Interpace Diagnostics Group and related companies with MarketBeat.com's FREE daily email newsletter.